LONG-TERM FOLLOW-UP STUDY OF PATIENTS WITH SPINAL MUSCULAR ATROPHY RECEIVING RISDIPLAM TREATMENT
Brief description of study
This study will evaluate the long-term safety and effectiveness of risdiplam (Evrysdi?), prescribed on the basis of the U.S. Package Insert (USPI) and clinician judgement, in adult and pediatric spinal muscular atrophy (SMA) patients.
Clinical Study Identifier: s22-00184
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
